目的 探讨保心宁胶囊联合美西律治疗慢性室性心律失常的临床疗效。方法 选取2016年7月-2018年7月郑州市第七人民医院接诊的240例慢性室性心律失常患者，根据入组顺序分成对照组和治疗组，每组各120例。对照组患者口服盐酸美西律片，4片/次，2次/d。治疗组在对照组治疗基础上口服保心宁胶囊，3粒/次，3次/d。两组患者均连续治疗2个月。观察两组的临床疗效，比较两组治疗前后动态心电图指标、血清生化指标的变化情况。结果 治疗后，对照组和治疗组的总有效率分别是90.83%、97.50%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者ST段压低持续时间、室性早搏次数、QTc间期均较治疗前显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组这些动态心电图指标低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者血清氨基末端脑钠肽前体（NT-proBNP）和超敏C反应蛋白（hs-CRP）水平均较治疗前显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组NT-proBNP、hs-CRP水平低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 保心宁胶囊联合美西律治疗慢性室性心律失常具有较好的临床疗效，可显著改善动态心电图指标，降低血清NT-proBNP和hs-CRP水平，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Baoxinning Capsules combined with mexiletine in treatment of chronic ventricular arrhythmia. Methods Patients (240 cases) with chronic ventricular arrhythmia in the 7th People's Hospital of Zhengzhou from July 2016 to July 2018 were divided into control (120 cases) and treatment (120 cases) groups according to the order of enrollment. Patients in the control group were po administered with Mexiletine Hydrochloride Tabltes, 4 tablets/time, twice daily. Patients in the treatment group were po administered with Baoxinning Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and the changes of dynamic electrocardiogram and serum biochemical indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 90.83% and 97.50%, respectively, and there were differences between two groups (P < 0.05). After treatment, the duration of ST segment depression, the number of ventricular premature beats, and the QTc interval in both groups were significantly reduced compared with those before treatment, and there were differences in the same group (P < 0.05). After treatment, the levels of those dynamic electrocardiogram indicators in the treatment group were lower than those in the control group, and there were differences between two groups (P < 0.05). After treatment, NT-proBNP and hs-CRP in both groups were significantly reduced compared with those before treatment, and there were differences in the same group (P < 0.05). After treatment, NT-proBNP and hs-CRP in the treatment group were lower than those in the control group, and there were differences between two groups (P < 0.05). Conclusion Baoxinning Capsules combined with mexiletine good clinical efficacy in treatment of chronic ventricular arrhythmia, and can significantly improve the dynamic electrocardiogram indexes, and also can reduce serum NT-proBNP and hs-CRP levels, which has a certain clinical application value.